HUP0003922A2 - Use of thiazolidinediones for the treatment of hyperglycaemia - Google Patents
Use of thiazolidinediones for the treatment of hyperglycaemiaInfo
- Publication number
- HUP0003922A2 HUP0003922A2 HU0003922A HUP0003922A HUP0003922A2 HU P0003922 A2 HUP0003922 A2 HU P0003922A2 HU 0003922 A HU0003922 A HU 0003922A HU P0003922 A HUP0003922 A HU P0003922A HU P0003922 A2 HUP0003922 A2 HU P0003922A2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- insulin sensitizer
- hyperglycaemia
- thiazolidinediones
- hyperglycemia
- Prior art date
Links
- 201000001421 hyperglycemia Diseases 0.000 title abstract 3
- 229940123464 Thiazolidinedione Drugs 0.000 title 1
- 150000001467 thiazolidinediones Chemical class 0.000 title 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
A találmány tárgya eljárás olyan hyperglykaemia, különösen koplalásoshyperglykaemia kezelésére, amelyben a plazma glükóz koncentrációk anormál szinttől legfeljebb 126 mg/dl-ig terjednek, amelynek során egyilyen kezelést igénylő emlősnek beadják egy inzulin szen- zibilizátorhatásos, nemtoxikus és gyógyászatilag elfogadható mennyiségét. Atalálmány szerinti eljárásban alkalmazott inzulin szenzibilizátorelőnyösen egy dioxo-tiazolidin inzulin szenzibilizátor,legelőnyösebben 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi)-benzil]-2,4-dioxo- -tiazolidin. ÓThe subject of the invention is a method for the treatment of hyperglycemia, especially fasting hyperglycemia, in which plasma glucose concentrations range from an abnormal level to a maximum of 126 mg/dl, during which a non-toxic and medically acceptable amount of an insulin sensitizer is administered to a mammal in need of such treatment. The insulin sensitizer used in the method according to the invention is preferably a dioxothiazolidine insulin sensitizer, most preferably 5-[4-{2-[N-methyl-N-(2-pyridyl)amino]-ethoxy)benzyl]-2,4-dioxo- -thiazolidine. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721693.1A GB9721693D0 (en) | 1997-10-13 | 1997-10-13 | Novel treatment |
| PCT/GB1998/003064 WO1999018943A1 (en) | 1997-10-13 | 1998-10-12 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0003922A2 true HUP0003922A2 (en) | 2001-10-28 |
| HUP0003922A3 HUP0003922A3 (en) | 2001-12-28 |
Family
ID=10820482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003922A HUP0003922A3 (en) | 1997-10-13 | 1998-10-12 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1023056A1 (en) |
| JP (1) | JP2001519382A (en) |
| KR (1) | KR20010024481A (en) |
| CN (1) | CN1281359A (en) |
| AP (1) | AP2000001787A0 (en) |
| AU (1) | AU9547098A (en) |
| BG (1) | BG104404A (en) |
| BR (1) | BR9815219A (en) |
| CA (1) | CA2306086A1 (en) |
| CZ (1) | CZ20001297A3 (en) |
| EA (1) | EA002659B1 (en) |
| GB (1) | GB9721693D0 (en) |
| HR (1) | HRP20000255A2 (en) |
| HU (1) | HUP0003922A3 (en) |
| ID (1) | ID24521A (en) |
| IL (1) | IL135513A0 (en) |
| NO (1) | NO20001898L (en) |
| NZ (1) | NZ503862A (en) |
| OA (1) | OA11683A (en) |
| PL (1) | PL339813A1 (en) |
| SK (1) | SK5312000A3 (en) |
| TR (1) | TR200000958T2 (en) |
| WO (1) | WO1999018943A1 (en) |
| YU (1) | YU28800A (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3856378T2 (en) * | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
-
1997
- 1997-10-13 GB GBGB9721693.1A patent/GB9721693D0/en not_active Ceased
-
1998
- 1998-10-12 SK SK531-2000A patent/SK5312000A3/en unknown
- 1998-10-12 TR TR2000/00958T patent/TR200000958T2/en unknown
- 1998-10-12 WO PCT/GB1998/003064 patent/WO1999018943A1/en not_active Application Discontinuation
- 1998-10-12 CA CA002306086A patent/CA2306086A1/en not_active Abandoned
- 1998-10-12 EA EA200000419A patent/EA002659B1/en not_active IP Right Cessation
- 1998-10-12 BR BR9815219-0A patent/BR9815219A/en not_active Application Discontinuation
- 1998-10-12 EP EP98949086A patent/EP1023056A1/en not_active Withdrawn
- 1998-10-12 KR KR1020007003934A patent/KR20010024481A/en not_active Application Discontinuation
- 1998-10-12 HU HU0003922A patent/HUP0003922A3/en unknown
- 1998-10-12 OA OA1200000108A patent/OA11683A/en unknown
- 1998-10-12 AU AU95470/98A patent/AU9547098A/en not_active Abandoned
- 1998-10-12 ID IDW20000669A patent/ID24521A/en unknown
- 1998-10-12 NZ NZ503862A patent/NZ503862A/en unknown
- 1998-10-12 IL IL13551398A patent/IL135513A0/en unknown
- 1998-10-12 CZ CZ20001297A patent/CZ20001297A3/en unknown
- 1998-10-12 CN CN98812083A patent/CN1281359A/en active Pending
- 1998-10-12 JP JP2000515578A patent/JP2001519382A/en active Pending
- 1998-10-12 PL PL98339813A patent/PL339813A1/en unknown
- 1998-10-12 YU YU28800A patent/YU28800A/en unknown
- 1998-10-12 AP APAP/P/2000/001787A patent/AP2000001787A0/en unknown
-
2000
- 2000-04-12 NO NO20001898A patent/NO20001898L/en not_active Application Discontinuation
- 2000-05-02 HR HR20000255A patent/HRP20000255A2/en not_active Application Discontinuation
- 2000-05-05 BG BG104404A patent/BG104404A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BG104404A (en) | 2000-12-29 |
| JP2001519382A (en) | 2001-10-23 |
| EA200000419A1 (en) | 2000-10-30 |
| ID24521A (en) | 2000-07-20 |
| NO20001898D0 (en) | 2000-04-12 |
| NZ503862A (en) | 2003-01-31 |
| EP1023056A1 (en) | 2000-08-02 |
| IL135513A0 (en) | 2001-05-20 |
| WO1999018943A1 (en) | 1999-04-22 |
| OA11683A (en) | 2005-01-12 |
| YU28800A (en) | 2003-02-28 |
| SK5312000A3 (en) | 2000-09-12 |
| BR9815219A (en) | 2001-01-02 |
| AP2000001787A0 (en) | 2000-06-30 |
| CN1281359A (en) | 2001-01-24 |
| CZ20001297A3 (en) | 2001-08-15 |
| HUP0003922A3 (en) | 2001-12-28 |
| NO20001898L (en) | 2000-06-09 |
| GB9721693D0 (en) | 1997-12-10 |
| AU9547098A (en) | 1999-05-03 |
| HRP20000255A2 (en) | 2001-02-28 |
| KR20010024481A (en) | 2001-03-26 |
| EA002659B1 (en) | 2002-08-29 |
| CA2306086A1 (en) | 1999-04-22 |
| TR200000958T2 (en) | 2000-08-21 |
| PL339813A1 (en) | 2001-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200268853A1 (en) | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment | |
| RU2189233C2 (en) | Use of effectors decreasing activity of dipeptidyl-peptidase (dp iv) and enzyme dp iv respectively with similar activity for decrease of blood glucose level | |
| HUP0003876A2 (en) | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes | |
| HUP0301194A2 (en) | Pharmaceutical compositions containing combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents and their use for the treatment of diabete mellitus | |
| MY129897A (en) | Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus | |
| Okayasu et al. | Decision tree for the management of periimplant diseases | |
| BR9504452A (en) | Pharmaceutical compound and formulation | |
| NO944803L (en) | Controlled release pharmaceutical preparation | |
| WO1999013875A8 (en) | Use of nitroxides for the treatment of essential hypertension | |
| CA2071629A1 (en) | Use of insulin sensitizing agents to treat hypertension | |
| HUP0003629A2 (en) | Synergic pharmaceutical composition for the treatment of diabetes containing thiazolidinedione, insulin secretagogue and diguanide | |
| HUP0003260A2 (en) | Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin | |
| NO20083276L (en) | Treatment of diabetes with thiazolidinedione and sulfonylurea | |
| CY1107745T1 (en) | TREATMENT OF DIABETES WITH THIAZOLIDINODION AND SULFONYLURIA | |
| HUP0203682A2 (en) | Method for administering a phosphodiesterase 4 inhibitor | |
| NZ513922A (en) | Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione | |
| HUP0003922A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| HUP0003626A2 (en) | Pharmaceutical composition for treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
| HUP0003673A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| AP9901720A0 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. | |
| HUP0301137A2 (en) | Thiazolidinedione salt for treatment of diabetes mellitus, process for its preparation and pharmaceutical composition containing the same | |
| BR0112984A (en) | Thiazolidinedione derivative tartrate salts | |
| BR0112982A (en) | Thiazolidinedione derivative tartrate salt | |
| HUP0301103A2 (en) | Treatment and prevention of cardiac insulin resistance associated conditions | |
| AP1580A (en) | Sustained release compositions comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |